While a phase II clinical study with a CCR9-inhibitor suggests a therapeutic benefit for Crohn's disease patients [8], our results strongly suggest that this form of therapeutic intervention could have detrimental effects when offered to patients that suffer from ulcerative large intestinal-specific inflammation. The gene discussed is CCR9; the disease is Crohn disease.